LUF6000A3 AR modulator CAS# 890087-21-5 |
- HG-10-102-01
Catalog No.:BCC4271
CAS No.:1351758-81-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 890087-21-5 | SDF | Download SDF |
PubChem ID | 11711282 | Appearance | Powder |
Formula | C22H20Cl2N4 | M.Wt | 411.33 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 14.29 mg/mL (34.74 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 2-cyclohexyl-N-(3,4-dichlorophenyl)-3H-imidazo[4,5-c]quinolin-4-amine | ||
SMILES | C1CCC(CC1)C2=NC3=C(N2)C(=NC4=CC=CC=C43)NC5=CC(=C(C=C5)Cl)Cl | ||
Standard InChIKey | UWJVRSIGHHSDSJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H20Cl2N4/c23-16-11-10-14(12-17(16)24)25-22-20-19(15-8-4-5-9-18(15)26-22)27-21(28-20)13-6-2-1-3-7-13/h4-5,8-13H,1-3,6-7H2,(H,25,26)(H,27,28) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
LUF6000 Dilution Calculator
LUF6000 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4311 mL | 12.1557 mL | 24.3114 mL | 48.6228 mL | 60.7785 mL |
5 mM | 0.4862 mL | 2.4311 mL | 4.8623 mL | 9.7246 mL | 12.1557 mL |
10 mM | 0.2431 mL | 1.2156 mL | 2.4311 mL | 4.8623 mL | 6.0778 mL |
50 mM | 0.0486 mL | 0.2431 mL | 0.4862 mL | 0.9725 mL | 1.2156 mL |
100 mM | 0.0243 mL | 0.1216 mL | 0.2431 mL | 0.4862 mL | 0.6078 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR). LUF6000 was found to be an allosteric enhancer of Emax of structurally diverse agonists at the A3 AR, being more effective for low-Emax agonists than for high-Emax agonists. LUF6000 exerted an Emax-enhancing effect at a concentration of 0.1 microM or higher, and was shown to increase the Emax of Cl-IB-MECA and other low-efficacy agonists to a larger extent than that of the high-efficacy agonist NECA. Interestingly, LUF6000 converted a nucleoside A3 AR antagonist MRS542, but not a non-nucleoside antagonist MRS1220, into an agonist.
- 2'-Deoxyinosine
Catalog No.:BCN8544
CAS No.:890-38-0
- 2,4-Dihydroxyacetophenone
Catalog No.:BCN4441
CAS No.:89-84-9
- Thymol
Catalog No.:BCN3794
CAS No.:89-83-8
- Pulegone
Catalog No.:BCN3856
CAS No.:89-82-7
- (+)-Menthone
Catalog No.:BCC9239
CAS No.:89-80-5
- Neoisomenthol
Catalog No.:BCC8169
CAS No.:20752-34-5
- Mesalamine
Catalog No.:BCC4798
CAS No.:89-57-6
- Edaravone
Catalog No.:BCC2480
CAS No.:89-25-8
- Quinolinic acid
Catalog No.:BCC6573
CAS No.:89-00-9
- Dipsanoside B
Catalog No.:BCN2878
CAS No.:889678-64-2
- Dipsanoside A
Catalog No.:BCN2877
CAS No.:889678-62-0
- Mogrol
Catalog No.:BCN8446
CAS No.:88930-15-8
- Nutlin-3
Catalog No.:BCC2254
CAS No.:890090-75-2
- WDR5 0103
Catalog No.:BCC5626
CAS No.:890190-22-4
- Dregeoside A11
Catalog No.:BCN3993
CAS No.:89020-11-1
- erythro-Guaiacylglycerol beta-coniferyl ether
Catalog No.:BCN1315
CAS No.:890317-92-7
- VU 29
Catalog No.:BCC7936
CAS No.:890764-36-0
- VU 1545
Catalog No.:BCC7649
CAS No.:890764-63-3
- ML 349
Catalog No.:BCC5612
CAS No.:890819-86-0
- GSK 650394
Catalog No.:BCC4070
CAS No.:890842-28-1
- 24,25-Epoxytirucall-7-en-3,23-dione
Catalog No.:BCN4437
CAS No.:890928-81-1
- BAMB-4
Catalog No.:BCC5428
CAS No.:891025-25-5
- 4-O-Demethylisokadsurenin D
Catalog No.:BCN6650
CAS No.:89104-59-6
- Odoratisol A
Catalog No.:BCN7813
CAS No.:891182-93-7
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000.[Pubmed:25868747]
Bioorg Med Chem. 2015 Jul 15;23(14):4065-71.
The search for G protein-coupled receptors (GPCRs) allosteric modulators represents an active research field in medicinal chemistry. Allosteric modulators usually exert their activity only in the presence of the orthosteric ligand by binding to protein sites topographically different from the orthosteric cleft. They therefore offer potentially therapeutic advantages by selectively influencing tissue responses only when the endogenous agonist is present. The prediction of putative allosteric site location, however, is a challenging task. In facts, they are usually located in regions showing more structural variation among the family members. In the present work, we applied the recently developed Supervised Molecular Dynamics (SuMD) methodology to interpret at the molecular level the positive allosteric modulation mediated by LUF6000 toward the human adenosine A3 receptor (hA3 AR). Our data suggest at least two possible mechanisms to explain the experimental data available. This study represent, to the best of our knowledge, the first case reported of an allosteric recognition mechanism depicted by means of molecular dynamics simulations.
Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.[Pubmed:19077268]
BMC Pharmacol. 2008 Dec 12;8:20.
BACKGROUND: A series of 1H-imidazo- [4,5-c]quinolin-4-amine derivatives, represented by LUF6000 (N-(3,4-dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine), are allosteric modulators of the human A3 adenosine receptor (AR). Here we studied the modulation by LUF6000 of the maximum effect (Emax) of structurally diverse agonists at the A3 AR stably expressed in CHO cells. RESULTS: In an assay of [35S]GTPgammaS binding, the Emax of the A3 AR agonist Cl-IB-MECA at the A3 AR was lower than that of the non-selective AR agonist NECA. LUF6000 exerted an Emax-enhancing effect at a concentration of 0.1 microM or higher, and was shown to increase the Emax of Cl-IB-MECA and other low-efficacy agonists to a larger extent than that of the high-efficacy agonist NECA. Interestingly, LUF6000 converted a nucleoside A3 AR antagonist MRS542, but not a non-nucleoside antagonist MRS1220, into an agonist. LUF6000 alone did not show any effect. Mathematical modeling was performed to explain the differential effects of LUF6000 on agonists with various Emax. A simple explanation for the observation that LUF6000 has a much stronger effect on Cl-IB-MECA than on NECA derived from the mathematical modeling is that NECA has relatively strong intrinsic efficacy, such that the response is already close to the maximum response. Therefore, LUF6000 cannot enhance Emax much further. CONCLUSION: LUF6000 was found to be an allosteric enhancer of Emax of structurally diverse agonists at the A3 AR, being more effective for low-Emax agonists than for high-Emax agonists. LUF6000 was demonstrated to convert an antagonist into an agonist, which represents the first example in G protein-coupled receptors. The observations from the present study are consistent with that predicted by mathematical modeling.